Context Therapeutics
CNTX
22 hedge funds and large institutions have $3.58M invested in Context Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
1,039% more capital inflows, than outflows
Capital inflows: $921K | Capital outflows: $80.9K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
5.96% more ownership
Funds ownership: 8.06% → 14.02% (+6%)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ally Bridge Group
New York
|
+$556K |
| 2 |
Affinity Asset Advisors
New York
|
+$228K |
| 3 |
UBS O'Connor
Chicago,
Illinois
|
+$55.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$40.6K |
| 5 |
Clear Harbor Asset Management
Stamford,
Connecticut
|
+$30.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$24.5K |
| 2 |
Virtu Financial
New York
|
-$23K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.8K |
| 4 |
Two Sigma Advisers
New York
|
-$9.11K |
| 5 |
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$4.67K |
CNTX Hedge Fund Activity: Q2 2023 in Review
22 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q2 2023, worth a combined $3.58M — up 396% from $723K a quarter earlier.
Fund positioning in CNTX was balanced in Q2 2023: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Ally Bridge Group, opening a new position worth an estimated $556K. The largest seller was Two Sigma Investments, cutting an estimated $24.5K.
- 22 institutional investors held Context Therapeutics (CNTX) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $3.58M of Context Therapeutics stock for Q2 2023, up 396% quarter-over-quarter.
- 5 funds opened new Context Therapeutics positions in Q2 2023 and 5 closed out, a net change of 0 holders.
- The largest Context Therapeutics buyer in Q2 2023 was Ally Bridge Group, an estimated $556K added.
- The largest Context Therapeutics seller in Q2 2023 was Two Sigma Investments, an estimated $24.5K sold.
Based on aggregated 13F filings for Q2 2023.